Synergistic apoptosis in head and neck squamous cell carcinoma cells by co-inhibition of insulin-like growth factor-1 receptor signaling and compensatory signaling pathways

Head and Neck

Volumn 37, Issue 12, 2015, Pages 1722-1732

  Axelrod, Mark J ^a   Mendez, Rolando E ^a   Khalil, Ashraf ^a,b   Leimgruber, Stephanie S ^c   Sharlow, Elizabeth R ^c   Capaldo, Brian ^a   Conaway, Mark ^c   Gioeli, Daniel G ^a   Weber, Michael J ^a   Jameson, Mark J ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b MENOUFIA UNIVERSITY   (Egypt)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

combination therapy; compensatory signaling; drug resistance; head and neck squamous cell carcinoma; insulin like growth factor 1 receptor

Indexed keywords

1 [4 [(5 CYCLOPROPYL 1H PYRAZOL 3 YL)AMINO]PYRROLO[2,1 F][1,2,4]TRIAZIN 2 YL] N (6 FLUORO 3 PYRIDINYL) 2 METHYL 2 PYRROLIDINECARBOXAMIDE; 2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; 4 [1 (3 FLUOROBENZYL) 5 INDAZOLYLAMINO] 5 METHYLPYRROLO[2,1 F][1,2,4]TRIAZINE 6 CARBAMIC ACID 3 MORPHOLINOMETHYL ESTER; 4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; ANTINEOPLASTIC AGENT; AT 7867; CASPASE 3; CRIZOTINIB; DASATINIB; FORETINIB; LINSITINIB; MKK 2206; PANOBINOSTAT; PROTEIN KINASE B; SERDEMETAN; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; VORINOSTAT; (4-((1-(3-FLUOROPHENYL)METHYL)-1H-INDAZOL-5-YLAMINO)-5-METHYLPYRROLO(2,1-F)(1,2,4)TRIAZIN-6-YL)CARBAMIC ACID 3-MORPHOLINYLMETHYL ESTER; CARBAMIC ACID DERIVATIVE; PYRAZOLE DERIVATIVE; TRIAZINE DERIVATIVE;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOLYSIS; DRUG POTENTIATION; ENZYME DEGRADATION; FLOW CYTOMETRY; GROWTH INHIBITION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; CELL CULTURE TECHNIQUE; DRUG EFFECTS; DRUG RESISTANCE; HEAD AND NECK NEOPLASMS; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARBAMATES; CARCINOMA, SQUAMOUS CELL; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; DASATINIB; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HEAD AND NECK NEOPLASMS; HUMANS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZOLES; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; TRIAZINES;

EID: 84954374160     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23822     Document Type: Article

References (35)

1. Berns K, Bernards R,. Understanding resistance to targeted cancer drugs through loss of function genetic screens. Drug Resist Updat 2012; 15: 268-275.
2. Shi H, Hugo W, Kong X, et al., Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 2014; 4: 80-93.
3. Sequist LV, Waltman BA, Dias-Santagata D, et al., Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3: 75ra26.
4. Ohashi K, Sequist LV, Arcila ME, et al., Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A 2012; 109: E2127-E2133.
5. Chandarlapaty S,. Negative feedback and adaptive resistance to the targeted therapy of cancer. Cancer Discov 2012; 2: 311-319.
6. Chandarlapaty S, Sawai A, Scaltriti M, et al., AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011; 19: 58-71.
7. Jameson MJ, Beckler AD, Taniguchi LE, et al., Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells. Mol Cancer Ther 2011; 10: 2124-2134.
8. Muranen T, Selfors LM, Worster DT, et al., Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 2012; 21: 227-239.
9. Gioeli D, Wunderlich W, Sebolt-Leopold J, et al., Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancer. Mol Cancer Ther 2011; 10: 1581-1590.
10. Ouban A, Muraca P, Yeatman T, Coppola D,. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol 2003; 34: 803-808.
11. Yee D,. Insulin-like growth factor receptor inhibitors: baby or the bathwater? J Natl Cancer Inst 2012; 104: 975-981.
12. Roller DG, Axelrod M, Capaldo BJ, et al., Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma. Mol Cancer Ther 2012; 11: 2505-2515.
13. Axelrod M, Gordon VL, Conaway M, et al., Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanisms. Oncotarget 2013; 4: 622-635.
14. Axelrod M, Ou Z, Brett LK, et al., Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma. Leukemia 2014; 28: 407-410.
15. Axelrod MJ, Gordon V, Mendez RE, et al., p70S6 kinase is a critical node that integrates HER-family and PI3 kinase signaling networks. Cell Signal 2014; 26: 1627-1635.
16. Gordon V, Bhadel S, Wunderlich W, et al., CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation. Mol Endocrinol 2010; 24: 2267-2280.
17. Warnes GR, Bolker B, Bonebakker L, et al., Gplots: various R programming tools for plotting data. In:, Warnes GR, editor. R package version 2.11.3. 2013.
18. Suzuki R, Shimodaira H,. Pvclust: hierarchical clustering with p-values via multiscale bootstrap resampling. 2011.
19. Bliss C,. The toxicity of poisons applied jointly. Ann Appl Biol 1939; 26: 585-615.
20. Buettner R, Mesa T, Vultur A, Lee F, Jove R,. Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells. Mol Cancer Res 2008; 6: 1766-1774.
21. Dayyani F, Parikh NU, Varkaris AS, et al., Combined inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways. PLoS One 2012; 7: e51189.
22. Kitagawa D, Yokota K, Gouda M, et al., Activity-based kinase profiling of approved tyrosine kinase inhibitors. Genes Cells 2013; 18: 110-122.
23. Green TP, Fennell M, Whittaker R, et al., Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol 2009; 3: 248-261.
24. Held MA, Langdon CG, Platt JT, et al., Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov 2013; 3: 52-67.
25. Sun DF, Zhang YJ, Tian XQ, Chen YX, Fang JY,. Inhibition of mTOR signalling potentiates the effects of trichostatin A in human gastric cancer cell lines by promoting histone acetylation. Cell Biol Int 2014; 38: 50-63.
26. Wedel S, Hudak L, Seibel JM, et al., Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells. Clin Exp Metastasis 2011; 28: 479-491.
27. Yi YW, Hong W, Kang HJ, et al., Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells. J Cell Mol Med 2013; 17: 648-656.
28. Glaysher S, Bolton LM, Johnson P, et al., Targeting EGFR and PI3K pathways in ovarian cancer. Br J Cancer 2013; 109: 1786-1794.
29. Festuccia C, Gravina GL, Muzi P, et al., Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors. Prostate 2008; 68: 965-974.
30. Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, Lee HY,. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 2007; 13: 2795-2803.
31. Galer CE, Corey CL, Wang Z, et al., Dual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma. Head Neck 2011; 33: 189-198.
32. Kim WY, Prudkin L, Feng L, et al., Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors. Cancer 2012; 118: 3993-4003.
33. Peterson JE, Jelinek T, Kaleko M, Siddle K, Weber MJ,. c phosphorylation and activation of the IGF-I receptor in src-transformed cells. J Biol Chem 1994; 269: 27315-27321.
34. Davies SP, Reddy H, Caivano M, Cohen P,. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351 (Pt 1): 95-105.
35. Cripps C, Winquist E, Devries MC, Stys-Norman D, Gilbert R,; Head and Neck Cancer Disease Site Group. Epidermal growth factor receptor targeted therapy in stage III and IV head and neck cancer. Curr Oncol 2010; 17: 37-48.